September 28, 2017
Mayo Clinic in the News Weekly Highlights
By Emily Blahnik 
Mayo Clinic in the News is a weekly highlights summary of major media coverage. If you would like to be added to the weekly distribution list, send a note to Emily Blahnik with this subject line: SUBSCRIBE to Mayo Clinic in the News. Editor, Karl Oestreich; Assistant Editor: Emily Blahnik Washington Post Letting a dog sleep on your bed does not actually […]
View full entry
Tags: Acorda Therapeutics, Addiction Now, Alzforum, alzheimer's disease, Amazon Alexa, Arizona Daily Sun, artificial Intelligence, Barron News-Shield, Becker’s Hospital Review, birth defects, Bloomington Pantagraph, brain cancer
April 24, 2013
Mayo Clinic and Acorda Therapeutics Announce Initiation of Phase 1 Trial of Remyelinating Antibody in People with Multiple Sclerosis
By Logan Lafferty 
Mayo Clinic and Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS)… “This remyelinating antibody, if successful in clinical trials and approved, would be a novel approach to treating people with […]
View full entry
Tags: Acorda Therapeutics, antibody, chronic neurologic deficits, clinical trial, Dr. Moses Rodriguez, MS, multiple sclerosis, rHIgM22, Wall Street Journal